Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C

Summary

The purpose of this study is to examine the rapid virologic response (RVR) at combination therapy (CT) Week 4 between groups receiving a standard combination peginterferon alfa-2b/viramidine dosing regimen versus a cohort that receives 4 weeks of viramidine monotherapy prior to the start of peginterferon alfa-2b/viramidine combination therapy.

Timeline

Start

2005-11

Primary completion

—

Completion

2007-05

Outcome

Outcome not reported

Stopped: “Dose levels were determined to be subtherapeutic”

Drugs

Indications